Cargando…
COVID-19 and management of neuroimmunological disorders
The importance of reported neurological manifestations of coronavirus disease 2019 (COVID-19) is still unclear. Nevertheless, an immediate and ongoing neurological challenge posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy for existing neuroimmunological...
Autores principales: | Hartung, Hans-Peter, Aktas, Orhan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242886/ https://www.ncbi.nlm.nih.gov/pubmed/32444648 http://dx.doi.org/10.1038/s41582-020-0368-9 |
Ejemplares similares
-
Vaccination and immunotherapies in neuroimmunological diseases
por: Winkelmann, Alexander, et al.
Publicado: (2022) -
COVID-19 in children and adolescents with neuroimmunological disorders
por: Pessoa, Ingrid Lacerda, et al.
Publicado: (2022) -
Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders
por: Olivé-Cirera, Gemma, et al.
Publicado: (2021) -
COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?
por: Ferini-Strambi, Luigi, et al.
Publicado: (2020) -
Editorial: Cognitive Disorders in Neuroimmunological Diseases
por: Ziemssen, Tjalf, et al.
Publicado: (2020)